JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v6i1.2510 jpsim.v6i1.2510 Original Research Posaconazole as a Treatment for Rhinosinusitis Mucormycosis Khan Kamran Amir kkhan@nwgh.pk * Qureshi Sameed Ullah Khan Zuhra Naheed Raza Maryam Saleem Khan Imran Mohib North West General Hospital, Peshawar Pakistan Kidney & Liver Institute, Lahore *Correspondence: Kamran Amir Khan (kkhan@nwgh.pk) 10 03 2025 2025 6 1 47 51 28 04 2024 10 02 2025 22 02 2025 Copyright © 2025 The Author(s) 2025 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To determine the performance of Posaconazole as a salvage therapy in patients with rhino-orbital-cerebral mucormycosis.

 Methodology

After the ethical committee gave its approval, this cross-sectional study was performed at the Northwest General Hospital & Research Centre, Peshawar, Pakistan. It comprised of data of patients diagnosed with mucormycosis from January 2018 to June 2021. All the patients underwent surgical intervention and were given Posaconazole either as salvage therapy or along with Amphotericin B for the treatment of mucormycosis. Convenient sampling was used and a structured format was used for data collection. SPSS 21 was used for data analysis.

 Results

Out of the 16 patients, 14 patients improved with Posaconazole with a reduction in the lesions. All 16 patients underwent surgical procedure for debridement and given both Amphotericin and Posaconazole. One patient died due to sepsis, and another patient died due to complications of COVID-19 infection. The remaining 14 patients recovered from the surgery, one patient was lost to follow up, and one patient suffered a re-infection, but recovered with Posaconazole.

 Conclusion

The study highlights the benefit of using Posaconazole either as combined therapy, single use or as a step down therapy for mucormycosis with minimal side effects.

 Keywords Posaconazole mucormycosis fungal infection rhinosinusitis References Walther G, Wagner L, Kurzai O. Outbreaks of Mucorales and the Species Involved. Mycopathologia. 2020;185(5):765-81. Reid G, Lynch JP, Fishbein MC, Clark NM. Mucormycosis. Semin Respir Crit Care Med. 2020;41(1):99-114. Roden MM, Zaoutis TE, Buchanan WL. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53. Gamaletsou MN, Sipsas N V., Roilides E, Walsh TJ. Rhino-Orbital-Cerebral mucormycosis. Curr Infect Dis Rep. 2012;14(4):423-34. Cornely OA, Alastruey-Izquierdo A, Arenz D. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. Tissot F, Agrawal S, Pagano L. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433-44. Steimbach LM, Tonin FS, Virtuoso S, Borba HH, Sanches AC, Wiens A, et al. Efficacy and safety of amphotericin B lipid-based formulations—A systematic review and meta-analysis. Mycoses. 2017;60(3):146-54. Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs. 2020;80(7):671-95. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;10.3390/jof5010026 Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34. Jabeen K, Farooqi J, Mirza S, Denning D, Zafar A. Serious fungal infections in Pakistan. Eur J Clin Microbiol Infect Dis. 2017;36(6):949-56. Greenberg RN, Mullane K, Van Burik JAH, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126-33. Van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Erratum: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis. 2006;43(10):1376. Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200(6):1002-11.